Activation of mesangial cells by the phosphatase inhibitor vanadate. Potential implications for diabetic nephropathy.

Standard

Activation of mesangial cells by the phosphatase inhibitor vanadate. Potential implications for diabetic nephropathy. / Wenzel, Ulrich; Fouqueray, B; Biswas, P; Grandaliano, G; Choudhury, G G; Abboud, H E.

In: J CLIN INVEST, Vol. 95, No. 3, 3, 1995, p. 1244-1252.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Wenzel U, Fouqueray B, Biswas P, Grandaliano G, Choudhury GG, Abboud HE. Activation of mesangial cells by the phosphatase inhibitor vanadate. Potential implications for diabetic nephropathy. J CLIN INVEST. 1995;95(3):1244-1252. 3.

Bibtex

@article{ffde91937a5145b5bdf701cccb91abfc,
title = "Activation of mesangial cells by the phosphatase inhibitor vanadate. Potential implications for diabetic nephropathy.",
abstract = "The metalion vanadate has insulin-like effects and has been advocated for use in humans as a therapeutic modality for diabetes mellitus. However, since vanadate is a tyrosine phosphatase inhibitor, it may result in undesirable activation of target cells. We studied the effect of vanadate on human mesangial cells, an important target in diabetic nephropathy. Vanadate stimulated DNA synthesis and PDGF B chain gene expression. Vanadate also inhibited total tyrosine phosphatase activity and stimulated tyrosine phosphorylation of a set of cellular proteins. Two chemically and mechanistically dissimilar tyrosine kinase inhibitors, genistein and herbimycin A, blocked DNA synthesis induced by vanadate. Vanadate also stimulated phospholipase C and protein kinase C. Downregulation of protein kinase C abolished vanadate-induced DNA synthesis. Thus, vanadate-induced mitogenesis is dependent on tyrosine kinases and protein kinase C activation. The most likely mechanism for the effect of vanadate on these diverse processes involves the inhibition of cellular phosphotyrosine phosphatases. These studies demonstrating that vanadate activates mesangial cells may have major implications for the therapeutic potential of vanadate administration in diabetes. Although vanadate exerts beneficial insulin-like effects and potentiates the effect of insulin in sensitive tissue, it may result in undesirable activation of other target cells, such as mesangial cells.",
author = "Ulrich Wenzel and B Fouqueray and P Biswas and G Grandaliano and Choudhury, {G G} and Abboud, {H E}",
year = "1995",
language = "Deutsch",
volume = "95",
pages = "1244--1252",
journal = "J CLIN INVEST",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",

}

RIS

TY - JOUR

T1 - Activation of mesangial cells by the phosphatase inhibitor vanadate. Potential implications for diabetic nephropathy.

AU - Wenzel, Ulrich

AU - Fouqueray, B

AU - Biswas, P

AU - Grandaliano, G

AU - Choudhury, G G

AU - Abboud, H E

PY - 1995

Y1 - 1995

N2 - The metalion vanadate has insulin-like effects and has been advocated for use in humans as a therapeutic modality for diabetes mellitus. However, since vanadate is a tyrosine phosphatase inhibitor, it may result in undesirable activation of target cells. We studied the effect of vanadate on human mesangial cells, an important target in diabetic nephropathy. Vanadate stimulated DNA synthesis and PDGF B chain gene expression. Vanadate also inhibited total tyrosine phosphatase activity and stimulated tyrosine phosphorylation of a set of cellular proteins. Two chemically and mechanistically dissimilar tyrosine kinase inhibitors, genistein and herbimycin A, blocked DNA synthesis induced by vanadate. Vanadate also stimulated phospholipase C and protein kinase C. Downregulation of protein kinase C abolished vanadate-induced DNA synthesis. Thus, vanadate-induced mitogenesis is dependent on tyrosine kinases and protein kinase C activation. The most likely mechanism for the effect of vanadate on these diverse processes involves the inhibition of cellular phosphotyrosine phosphatases. These studies demonstrating that vanadate activates mesangial cells may have major implications for the therapeutic potential of vanadate administration in diabetes. Although vanadate exerts beneficial insulin-like effects and potentiates the effect of insulin in sensitive tissue, it may result in undesirable activation of other target cells, such as mesangial cells.

AB - The metalion vanadate has insulin-like effects and has been advocated for use in humans as a therapeutic modality for diabetes mellitus. However, since vanadate is a tyrosine phosphatase inhibitor, it may result in undesirable activation of target cells. We studied the effect of vanadate on human mesangial cells, an important target in diabetic nephropathy. Vanadate stimulated DNA synthesis and PDGF B chain gene expression. Vanadate also inhibited total tyrosine phosphatase activity and stimulated tyrosine phosphorylation of a set of cellular proteins. Two chemically and mechanistically dissimilar tyrosine kinase inhibitors, genistein and herbimycin A, blocked DNA synthesis induced by vanadate. Vanadate also stimulated phospholipase C and protein kinase C. Downregulation of protein kinase C abolished vanadate-induced DNA synthesis. Thus, vanadate-induced mitogenesis is dependent on tyrosine kinases and protein kinase C activation. The most likely mechanism for the effect of vanadate on these diverse processes involves the inhibition of cellular phosphotyrosine phosphatases. These studies demonstrating that vanadate activates mesangial cells may have major implications for the therapeutic potential of vanadate administration in diabetes. Although vanadate exerts beneficial insulin-like effects and potentiates the effect of insulin in sensitive tissue, it may result in undesirable activation of other target cells, such as mesangial cells.

M3 - SCORING: Zeitschriftenaufsatz

VL - 95

SP - 1244

EP - 1252

JO - J CLIN INVEST

JF - J CLIN INVEST

SN - 0021-9738

IS - 3

M1 - 3

ER -